

### Listing of Claims

1-8. (canceled)

9. (currently amended) A method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of WISP-1 antagonist, wherein said WISP-1 antagonist ~~is a WISP-1 antibody~~ comprises the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody secreted by the hybridoma deposited with ATCC as accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively.

10-12. (canceled)

13. (original) The method of claim 9, wherein said mammalian cells comprise cancer cells.

14. (original) The method of claim 13, wherein said mammalian cells comprise colon or colorectal cancer cells, breast cancer cells, lung cancer cells or brain cancer cells.

15-30. (canceled)

31. (new) The method of claim 9, wherein said monoclonal antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

32. (new) A method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of WISP-1 antagonist, wherein said WISP-1 antagonist comprises an anti-WISP-1 monoclonal antibody which binds to the same epitope as the epitope to which the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, binds.

33. (new) The method of claim 32, wherein said anti-WISP-1 monoclonal antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

34. (new) The method of claim 32, wherein said mammalian cells comprise cancer cells.

35. (new) The method of claim 34, wherein said mammalian cells comprise colon or colorectal cancer cells, breast cancer cells, lung cancer cells or brain cancer cells.

36. (new) A method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of WISP-1 antagonist, wherein said WISP-1 antagonist comprises a chimeric anti-WISP-1 antibody which specifically binds to WISP-1 polypeptide and comprises a sequence derived from the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively.

37. (new) The method of claim 36, wherein said derived sequence is the variable or hypervariable region of the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody.

38. (new) The method of claim 36, wherein said chimeric anti-WISP-1 antibody is a humanized antibody.

39. (new) The method of claim 36, wherein said mammalian cells comprise cancer cells.

40. (new) The method of claim 36, wherein said mammalian cells comprise colon or colorectal cancer cells, breast cancer cells, lung cancer cells or brain cancer cells.

41. (new) The method of claim 36, wherein said chimeric anti-WISP-1 antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.